N. Mesaros

发表

Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study

Martina Kovac, Lusiné Kostanyan, N. Mesaros, 2018, Human vaccines & immunotherapeutics.

Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial.

O. Vanderkooi, G. Zuccotti, F. Martinón-Torres, 2019, Vaccine.

Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa

T. Vesikari, N. Mesaros, B. Cheuvart, 2017, Human vaccines & immunotherapeutics.

Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study

Dong Ho Kim, P. Hwang, N. Mesaros, 2018, Human vaccines & immunotherapeutics.

Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer

N. Mesaros, Winnie Janssens, L. Hanssens, 2018, Expert review of vaccines.

Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants

Changgui Li, N. Mesaros, Naveen Karkada, 2016, Human vaccines & immunotherapeutics.

Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.

P. Lebecque, P. Nordmann, P. Tulkens, 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.

M. Knuf, J. Liese, N. Mesaros, 2018, Vaccine.

A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa.

P. Tulkens, N. Mesaros, F. Van Bambeke, 2007, The Journal of antimicrobial chemotherapy.

Persistence of Antibody Response Following a Booster Dose of Hib-MenC-TT Glycoconjugate Vaccine to Five Years: A Follow-up Study

Ly-Mee Yu, A. Pollard, M. Snape, 2012, The Pediatric infectious disease journal.

Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers

J. McVernon, E. Aris, H. Marshall, 2012, Human vaccines & immunotherapeutics.

Immunogenicity and Safety of an Investigational Combined Haemophilus influenzae Type B-Neisseria meningitidis Serogroups C and Y-Tetanus Toxoid Conjugate Vaccine

J. McVernon, E. Aris, H. Marshall, 2011, The Pediatric infectious disease journal.

Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants

N. Mesaros, Shailesh Mehta, Naveen Karkada, 2016, Human vaccines & immunotherapeutics.

Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations.

P. Tulkens, M. Mingeot-Leclercq, L. Piddock, 2007, The Journal of antimicrobial chemotherapy.

Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy.

L. Cámpora, N. Mesaros, H. Tseng, 2022, Vaccine.

Persistence of Immunity Following a Booster Dose of Haemophilus Influenzae Type B-Meningococcal Serogroup C Glycoconjugate Vaccine: Follow-up of a Randomized Controlled Trial

Ly-Mee Yu, A. Pollard, M. Snape, 2011, The Pediatric infectious disease journal.

Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.

O. Vanderkooi, G. Zuccotti, F. Martinón-Torres, 2021, Vaccine.

Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.

R. Frenck, N. Mesaros, M. Varman, 2017, Vaccine.

Antibody Persistence for up to 5 Years After a Fourth Dose of Haemophilus influenzae Type b and Neisseria Meningitidis Serogroups C and Y–Tetanus Toxoid Conjugate Vaccine (HibMenCY-TT) Given at 12–15 Months of Age

E. Aris, N. Mesaros, Jacqueline M. Miller, 2013, The Pediatric infectious disease journal.

Three-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type b (Hib)–Neisseria meningitidis Serogroup C-tetanus Toxoid Conjugate Vaccine in Hib-primed Toddlers

J. Ziegler, J. McVernon, H. Marshall, 2013, The Pediatric infectious disease journal.

IMMEDIATE AND LONGER TERM IMMUNOGENICITY OF A SINGLE DOSE OF THE COMBINED HAEMOPHILUS INFLUENZAE TYPE B-NEISSERIA MENINGITIDIS SEROGROUP C-TETANUS TOXOID CONJUGATE VACCINE IN PRIMED TODDLERS 12 TO 18 MONTHS OF AGE

J. Ziegler, J. McVernon, H. Marshall, 2011 .

Long-term antibody persistence against hepatitis B in adolescents 14–15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy

N. Mesaros, T. Schwarz, Winnie Janssens, 2018, Human vaccines & immunotherapeutics.

The safety profile of Haemophilus influenzae type b–Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY)

E. Aris, N. Mesaros, T. Nolan, 2012, Human vaccines & immunotherapeutics.

Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial

G. Dbaibo, N. Mesaros, S. Ghanem, 2013, Drugs & Aging.

Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.

Lusiné Kostanyan, N. Mesaros, S. Kuriyakose, 2018, Vaccine.

In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.

P. Tulkens, F. Jacobs, N. Mesaros, 2010, International journal of antimicrobial agents.

Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States

N. Mesaros, N. Klein, B. Cheuvart, 2019, Human vaccines & immunotherapeutics.

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

E. Kerwin, J. Tica, F. Struyf, 2022, The Journal of infectious diseases.

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience

N. Mesaros, Y. Baine, M. van der Wielen, 2011, Advances in preventive medicine.

Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in in

N. Mesaros, N. Klein, B. Cheuvart, 2018, Human vaccines & immunotherapeutics.

Combined Haemophilus Influenzae Type B-Neisseria Meningitidis Serogroup C Vaccine Is Immunogenic and Well Tolerated in Preterm Infants When Coadministered With Other Routinely Recommended Vaccines

J. Arístegui, N. Mesaros, J. Merino, 2011, The Pediatric infectious disease journal.

A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in th

S. Faust, A. Pollard, A. Finn, 2018, Vaccine.

Safety of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine when administered during pregnancy as part of the maternal immunization program in Brazil: a single center, observational, retrospective, cohort study

M. Sancovski, N. Mesaros, Yang Feng, 2019, Human vaccines & immunotherapeutics.

Five-year Antibody Persistence and Safety Following a Booster Dose of Combined Haemophilus influenzae Type b–Neisseria meningitidis Serogroup C–Tetanus Toxoid Conjugate Vaccine

N. Mesaros, M. Moro, J. García-Sicilia, 2012, The Pediatric infectious disease journal.

Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial.

O. Vanderkooi, G. Zuccotti, F. Martinón-Torres, 2019, Vaccine.

Investigating Tetanus, Diphtheria, Acellular Pertussis Vaccination During Pregnancy and Risk of Congenital Anomalies

L. Cámpora, C. Zheng, N. Mesaros, 2022, Infectious Diseases and Therapy.

Lasting immune memory against hepatitis B in 12–13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy

N. Mesaros, O. Van Der Meeren, P. Crasta, 2016, Human vaccines & immunotherapeutics.

Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.

M. Haranaka, N. Mesaros, M. David, 2023, Respiratory investigation.

119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated

E. Kerwin, J. Tica, N. Dezutter, 2020, Open Forum Infectious Diseases.